Credit Suisse’s Cascadian Therapeutics, Inc. CASC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-19,408
| Closed | -$72K | – | 4234 |
|
|
2017
Q4 | $72K | Sell |
19,408
-3,980
| -17% | -$16.3K | ﹤0.01% | 3881 |
|
|
2017
Q3 | $95K | Buy |
+23,388
| New | +$89.5K | ﹤0.01% | 4105 |
|
|
2017
Q2 | – | Sell |
-10,650
| Closed | -$44K | – | 4039 |
|
|
2017
Q1 | $44K | Buy |
+10,650
| New | +$44.8K | ﹤0.01% | 3752 |
|
|
2016
Q4 | – | Sell |
-4,816
| Closed | -$47K | – | 4318 |
|
|
2016
Q3 | $47K | Sell |
4,816
-56,306
| -92% | -$399K | ﹤0.01% | 4026 |
|
|
2016
Q2 | $345K | Buy |
61,122
+57,034
| +1,395% | +$387K | ﹤0.01% | 3632 |
|
|
2016
Q1 | $31K | Sell |
4,088
-7,525
| -65% | -$57.9K | ﹤0.01% | 3921 |
|
|
2015
Q4 | $155K | Buy |
11,613
+5,920
| +104% | +$102K | ﹤0.01% | 3984 |
|
|
2015
Q3 | $94K | Sell |
5,693
-5,689
| -50% | -$117K | ﹤0.01% | 4111 |
|
|
2015
Q2 | $255K | Buy |
11,382
+5,669
| +99% | +$89.7K | ﹤0.01% | 4095 |
|
|
2015
Q1 | $56K | Sell |
5,713
-5,659
| -50% | -$55.5K | ﹤0.01% | 4273 |
|
|
2014
Q4 | $129K | Buy |
11,372
+8,419
| +285% | +$91.4K | ﹤0.01% | 4390 |
|
|
2014
Q3 | $34K | Sell |
2,953
-5,081
| -63% | -$77.6K | ﹤0.01% | 4372 |
|
|
2014
Q2 | $156K | Sell |
8,034
-40,265
| -83% | -$710K | ﹤0.01% | 4445 |
|
|
2014
Q1 | $866K | Buy |
48,299
+37,445
| +345% | +$615K | ﹤0.01% | 3246 |
|
|
2013
Q4 | $115K | Buy |
+10,854
| New | +$121K | ﹤0.01% | 4453 |
|
|
2013
Q3 | – | Sell |
-26,560
| Closed | -$250K | – | 4457 |
|
|
2013
Q2 | $250K | Buy |
+26,560
| New | +$341K | ﹤0.01% | 3741 |
|
Credit Suisse's CASC Position: Q1 2018 in Review
Credit Suisse sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 19,408 shares — an estimated $72K sold.
Credit Suisse first reported a position in CASC in Q2 2013 and held it in 16 quarters. The position peaked at $866K in Q1 2014. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.
- Credit Suisse reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
- Credit Suisse sold 19,408 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $72K.
- Credit Suisse first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 16 quarters.
- Credit Suisse's Cascadian Therapeutics, Inc. position peaked at $866K in Q1 2014.
- 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.
Based on Credit Suisse's 13F filing for Q1 2018, filed 15 May 2018.